Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|September 15, 2021

Dr. Zorn discusses 3-year data on Aquablation

Author(s)Urology Times staff

“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.

In this video, Kevin Zorn, MD, FRCSC, FACS, discusses the findings and takeaways of the study, “Aquablation for benign prostatic hyperplasia in large prostates (80-150CC): 3-year results,” which was presented during the 2021 American Urological Association annual meeting. Zorn is an associate professor of urology at the University of Montreal, Canada.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

ByJoshua Lang, MD, MS

July 31st 2026

Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm

ByMatthew Galsky, MD

July 29th 2026

Adanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC

ByAdanma Ayanambakkam, MD, MS

July 28th 2026

Why accurate CIS diagnosis matters in bladder cancer care

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 27th 2026

Joshua Halpern, MD, MS, on the clinical role of mail-in semen analysis

ByJoshua Halpern, MD, MS

July 27th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

From hype to practice: Urologists assess AI's real impact